Seres Therapeutics/$MCRB
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Seres Therapeutics
Seres Therapeutics Inc is a clinical-stage biotechnology company focused on the development of live biotherapeutic candidates. Its pipeline includes candidates such as SER-155 and SER-603, aimed at preventing and treating bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases. The company operates as a single reportable segment, mainly developing microbiome-based therapies targeting bacterial infections, antimicrobial resistance, and gastrointestinal immune diseases.
- Ticker
- $MCRB
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 66
- Headquarters
- Cambridge, United States
- Website
- www.serestherapeutics.com
MCRB Metrics
BasicAdvanced
$15M
-
-$4.88
-
-
Price and volume
Market cap
$15M
52-week high
$29.98
52-week low
$1.35
Average daily volume
90K
Financial strength
Current ratio
1.648
Quick ratio
1.446
Long term debt to equity
1.083
Total debt to equity
1.675
Profitability
EBITDA (TTM)
-63.233
Gross margin (TTM)
-1,791.95%
Net profit margin (TTM)
-2,209.55%
Operating margin (TTM)
-3,115.15%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-39.52%
Return on equity (TTM)
-144.35%
Valuation
Price to revenue (TTM)
6.798
Price to book
0.71
Price to tangible book (TTM)
0.71
Growth
Revenue change (TTM)
505.41%
Earnings per share change (TTM)
-887.43%
3-year revenue growth (CAGR)
29.65%
10-year revenue growth (CAGR)
-19.56%
3-year earnings per share growth (CAGR)
-39.75%
10-year earnings per share growth (CAGR)
-19.64%
MCRB Financial Performance
Revenues and expenses
MCRB Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.